PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
Clinical trial NCT07025681 · RECRUITING
Trial details
- NCT number
- NCT07025681
- Sponsor
- Incepta Pharmaceuticals Ltd
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-24
- Primary completion
- 2025-09-30
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.